Gilead Sciences Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Gilead Sciences Bundle
Unlock Strategic Clarity
Gilead’s BCG Matrix preview teases which therapies are market leaders and which need a rethink—antivirals might be Stars, niche indications could be Question Marks. This sneak peek shows trends; the full report maps quadrant placements, data-backed moves, and a clear capital-allocation plan. Purchase the complete BCG Matrix for a Word report plus an Excel summary you can use immediately to steer strategy with confidence.
Stars
Biktarvy (HIV)
Biktarvy is Gilead’s lead HIV regimen and in 2024 remained the company’s top HIV product, with commanding market share and steady patient adds that place it in the high-share, high-growth quadrant. It still requires heavy promotion and payer/access work to defend switch wins and limit churn. Holding the line on adherence, tight payer contracts and accelerated global expansion will let it mature into an even larger cash engine.
Yescarta/Tecartus (CAR‑T)
Yescarta (2017) and Tecartus (2020) anchor Kite’s CAR‑T franchise in a cell‑therapy market growing ~23% CAGR to the end of the decade. Manufacturing scale and outcomes/center footprint (multiple GMP sites) give a competitive edge but demand heavy capex and ops focus. Gilead should keep investing to broaden labels and boost throughput. If executed, these assets can compound into a future cash cow.
Trodelvy (TROP‑2 ADC)
Trodelvy (TROP‑2 ADC) sits in star territory—rapid uptake since FDA approval in April 2020 and ongoing 2024 label-expansion efforts across breast‑cancer settings driving high growth and an expanding prescriber base. Strong randomized data underpin a compelling clinical story, but promotional and trial spend remain heavy to sustain access and sequencing. Continued investment should secure leadership before the ADC class crowds, capturing substantial near‑term market share.
INSTI‑led HIV Treatment Franchise
INSTI-led franchise centered on Biktarvy dominates an innovation-driven HIV market; Biktarvy exceeded $10 billion in annual sales in 2023, underpinning Gilead’s strong share. Share is high but continual lifecycle management and regimen switching require sustained R&D and commercial muscle. Invest in adherence tools, convenience (long-acting/formulations), and resistance coverage to sustain momentum and bank outsized cash later.
- Biktarvy >10B annual sales (2023)
- INSTI class drives majority of new starts (2024 uptake >60%)
- Priority: adherence, long-acting convenience, resistance coverage
Kite Cell Therapy Platform Scale
Kite's cell-therapy platform is a Star: its network, multi-site manufacturing and growing 2024 real-world data base drive adoption in an accelerating CAR-T market; however scaling demands high capex, elevated COGS and extensive site enablement, so cash use remains substantial. Keep reducing time-to-infusion and improving reliability to convert scale into durable margin and protect category leadership.
- Platform advantage: network, manufacturing, RWD (2024: broader real-world evidence supporting label expansions)
- Cash profile: high capex, significant COGS, site enablement
- Operational focus: lower time-to-infusion, increase reliability
- Strategic outcome: scale today protects leadership tomorrow
Star assets: $10B+ HIV franchise (INSTI >60% starts), CAR‑T ~23% CAGR, ADC rapid uptake
Biktarvy is a Star: >$10B sales (2023) with INSTI uptake >60% (2024), high share and growth but needs lifecycle investment. Kite’s CAR‑T (Yescarta/Tecartus) is a Star in a ~23% CAGR market, manufacturing scale drives adoption but demands capex. Trodelvy is a Star with rapid post‑2020 uptake and ongoing label expansions, requiring heavy promo and trial spend.
| Asset | 2023/24 metric | Key risk |
|---|---|---|
| Biktarvy | >$10B (2023); INSTI >60% starts (2024) | lifecycle mgmt |
| Kite | CAR‑T market ~23% CAGR | high capex/COGS |
| Trodelvy | rapid uptake since 2020 | promo/trial spend |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix for Gilead: spots Stars, Cash Cows, Question Marks and Dogs, with strategic invest/hold/divest guidance.
Customizable Excel Spreadsheet
One-page BCG Matrix for Gilead: instantly spot stars and dogs, simplify portfolio decisions for execs.
Cash Cows
Epclusa‑led HCV Franchise
Epclusa‑led HCV franchise sits in a mature market with dominant share, generating steady cashflow—2024 cash contribution estimated at roughly $1–1.5B—while treated volumes are drifting down (~20% y/y), yet margins remain attractive (~35–45%) due to low promotional needs. Milk efficiently, trim SKU and supply complexity, and allocate proceeds to fund oncology and long‑acting HIV growth bets.
Veklury (remdesivir)
Veklury (remdesivir) stabilized in 2024 as COVID demand normalized, yet continues to generate meaningful, low‑investment cash from steady hospital procurement and an established supply chain. Predictable purchasing patterns keep opex modest and inventory/seasonality management critical to avoid overspending. That recurring cash flow is being channeled to R&D without distracting management from core pipeline priorities.
Descovy for PrEP
Descovy for PrEP holds a high-share position in a relatively steady, policy-supported market—CDC estimates ~1.2 million people in the US are indicated for PrEP. Promotion is targeted and margins remain solid while Gilead defends access and adherence programs to preserve uptake. Monitor generic Truvada pressure and emerging long-acting injectables; harvest cash and invest only to maintain the franchise.
Vemlidy (HBV)
Vemlidy (HBV) is a mature, high-share product with durable demand and strong payer acceptance, delivering predictable returns and accounting for over $1B in annual net sales as of 2024; growth is low but share is high, fitting the Cash Cows quadrant. Focus is on optimizing contracting and manufacturing efficiency to preserve margins while keeping incremental R&D and commercial spend minimal.
- Market position: high share, low growth
- 2024 sales: >$1B global net product sales
- Strategy: optimize contracting & manufacturing
- Finance: reliable cash contributor, minimal incremental spend
Oseltamivir Royalties
Oseltamivir royalties sit squarely in Gilead’s Cash Cows quadrant: a seasonal, mature, low‑maintenance income stream generating steady inflows with minimal ongoing commercial effort from Gilead. Revenue is driven by predictable influenza seasons and licensing arrangements, allowing the company to keep paperwork streamlined and focus resources elsewhere. It’s classic milk‑it territory—maintain compliance, collect royalties, and redeploy capital into growth areas.
Unlock cash cows — harvest mature antivirals, reinvest in oncology and long-acting HIV
Epclusa, Veklury, Descovy (PrEP), Vemlidy and oseltamivir form Gilead’s Cash Cows: high share, low growth, predictable margins and steady cash generation in 2024 (Epclusa ~$1–1.5B; Vemlidy >$1B). Harvest and streamline SKUs/ops; reinvest proceeds into oncology and long‑acting HIV while monitoring competitive and generic risks.
| Product | 2024 metric |
|---|---|
| Epclusa | $1–1.5B cash contribution |
| Veklury | stable hospital demand |
| Descovy (PrEP) | ~1.2M US indicated |
| Vemlidy | >$1B net sales |
| Oseltamivir | seasonal royalties |
Full Transparency, Always
Gilead Sciences BCG Matrix
The file you're previewing here is the exact BCG Matrix report you'll receive after purchase—no watermarks, no placeholders, no surprises. It's fully formatted and analysis-ready, crafted for strategic clarity and quick decision-making. After buying, the same document is instantly downloadable and editable for presentations or planning. Ready to use, straight out of the box.
Dogs
Legacy HCV SKUs (non‑core, tail geos)
Legacy HCV SKUs in non‑core tail geos face low to declining growth, fragmented share and intense pricing pressure, turning them into operational drag that outweighs strategic value. WHO still estimates about 58 million people with chronic HCV, but treatment volumes and prices in these markets collapsed post‑peak, so sunset and SKU simplification to reclaim working capital is warranted. Turnaround spend is unlikely to pay back given shrinking demand and margin compression.
Zydelig (idelalisib)
Zydelig (idelalisib) carries significant safety baggage—FDA boxed warnings added in 2016 for hepatotoxicity, colitis, pneumonitis and intestinal perforation. The competitive oncology landscape (BTK, newer PI3K inhibitors, venetoclax) has constrained uptake; by 2024 idelalisib remains a niche, low-share product within Gilead’s oncology lineup. Minimize spend, consider divest/partner and do not chase marginal indications.
Viread (TDF) Legacy
Viread (TDF) has been off‑patent in key markets since 2018, and generic entry plus migration to TAF‑based regimens has driven steep price erosion—often exceeding 80% in competitive markets—and a collapse in volume growth. Market share is thin and growth is effectively nil; global sales are a fraction of peak levels. Maintain only essential supply commitments; any heavy investment becomes a near‑term cash trap.
Cayston (inhaled aztreonam)
Cayston (inhaled aztreonam) sits as a Dog in Gilead’s BCG: niche cystic fibrosis use, constrained patient pool, and limited uptake versus inhaled tobramycin and newer modulators; no clear growth catalysts are visible. Ongoing support and regulatory compliance costs can quietly creep, eroding margins. No expansion bets recommended given limited market leverage.
- Niche therapy, low volume
- Limited uptake vs competitors
- No clear growth catalysts
- Support/compliance costs risk
- No expansion bets
Filgotinib Footprint (ex‑US)
Filgotinib (Jyseleca) remains ex‑US only after the US filing was withdrawn and EMA/Japan approvals in 2020, leaving constrained labels and heavy class competition that cap upside.
With a small market share and slow uptake, continued promotional and access spend is a drag; tighten investment to must‑have markets and prioritize partnerships over sole funding.
- Position: Dog (low share, low growth)
- Regulatory: ex‑US approvals (EMA, Japan) since 2020
- Strategy: reduce spend; pursue partnerships/licensing
Cut legacy low-growth SKUs, rationalize costs and pursue partnerships or divestitures
Multiple legacy SKUs (HCV, Viread, Cayston, Zydelig, filgotinib) exhibit low growth, fragmentary share and margin pressure; WHO estimates 58 million chronic HCV cases but post‑peak treatment volumes collapsed. Safety/competition limit idelalisib and filgotinib upside; TDF faces generic erosion; recommend cost‑cut, SKU rationalization, partnerships or divestiture.
| Product | 2024 status | Market growth | Share | Action |
|---|---|---|---|---|
| Legacy HCV SKUs | Sunsetting | Declining | Low | SKU cut |
| Viread (TDF) | Post‑patent | Price erosion | Thin | Maintain minimal supply |
| Zydelig | Safety constrained | Flat/decline | Niche | Divest/partner |
| Cayston | Niche CF use | Low | Small | No expansion |
Question Marks
Sunlenca (lenacapavir, long‑acting HIV)
Sunlenca (lenacapavir) — FDA approved Aug 2022 for heavily treatment‑experienced, multidrug‑resistant HIV‑1 — is a Question Mark: its differentiated every‑6‑month dosing offers high growth potential but market share remains early. It consumes cash for launch, access programs and real‑world evidence, so Gilead must push indications and combination strategies to accelerate adoption. Scale fast or risk stalling behind other long‑acting rivals.
Hepcludex (bulevirtide, HDV)
Hepcludex (bulevirtide) addresses underserved HDV where WHO (2019) cites ~296 million chronic HBV carriers and ~5% co‑infection (~15 million), a small but meaningful market. EMA granted conditional approval in 2020 with selective regional approvals through 2024, showing regulatory momentum. Early traction is promising but share isn’t secured; invest in awareness, diagnostics and market access to win the beachhead before competitors arrive.
Trodelvy Earlier‑Line/Combo Expansions
Label expansions for Trodelvy could unlock step‑change volume but require costly, uncertain registrational trials; as of 2024 Trodelvy is supported by multiple ongoing Phase 3 programs. If pivotal data succeeds this franchise shifts toward star economics with materially higher peak sales; if not, margin and ROI compress sharply. Decision point: double down on the clearest signals and prune weaker programs.
Next‑Gen Cell Therapy (solid tumors)
Next‑Gen cell therapy for solid tumors is a Question Mark: high market upside but extremely tough biology; as of 2024 no CAR‑T is approved for solid tumors, and Gilead’s oncology play includes Kite (acquired 2017 for $11.9B), highlighting both commitment and risk. Early programs burn cash with unclear timelines to meaningful share; prioritize constructs with manufacturing and efficacy edge, kill fast if signals fade, scale if response durability shows.
- High upside / high risk
- No approved solid‑tumor CAR‑T (2024)
- Prioritize manufacturable, durable responders
- Kill fast; scale on durable responses
HBV Functional‑Cure Combos
Scientific rationale for HBV functional‑cure combos is strong but, as of 2024, clinical proof and a clear adoption pathway remain unconfirmed; Gilead continues heavy, long‑dated investment (R&D >$5B annually) while late‑stage combo readouts are pending. A positive breakthrough could convert this question mark into a future star; failure should trigger a pivot toward incremental optimization and cash conservation.
- WHO chronic HBV ~296M (2023)
- High R&D intensity; long ROI horizon
- Binary value: breakthrough → high upside; failure → de‑risk & conserve
Question marks: big upside, early share risk & heavy R&D - allocate, scale winners
Sunlenca, Hepcludex, Trodelvy label expansions, next‑gen solid‑tumor CAR‑T and HBV cure combos are Question Marks: high upside but early market share and heavy R&D spend (Gilead R&D >$5B/year) make outcomes binary; allocate selectively, scale winners, kill failures.
| Asset | 2024 status | Key metric |
|---|---|---|
| Sunlenca | Post‑launch | FDA Aug 2022 |
| Hepcludex | Regional approvals | HDV ~15M co‑infected |
| Trodelvy | Multiple Phase 3 | Pivotal readouts ongoing |